J J Scarisbrick

Summary

Country: UK

Publications

  1. ncbi request reprint Extracorporeal photopheresis in Sézary syndrome: hematologic parameters as predictors of response
    A V Evans
    Skin Tumour Unit, St John's Institute of Dermatology, St Thomas' Hospital, London, United Kingdom
    Blood 98:1298-301. 2001
  2. doi request reprint U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease
    J J Scarisbrick
    St John s Institute of Dermatology, St Thomas Hospital, London, U K
    Br J Dermatol 158:659-78. 2008
  3. doi request reprint U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma
    J J Scarisbrick
    University Hospital Birmingham, Birmingham B15 2TH, U K
    Br J Dermatol 168:192-200. 2013
  4. ncbi request reprint Clinical features and diagnosis of 42 travellers with cutaneous leishmaniasis
    J J Scarisbrick
    Department of Dermatology, Middlesex Hospital, Mortimer Street, London W1N 8AA, UK
    Travel Med Infect Dis 4:14-21. 2006
  5. ncbi request reprint Staging and management of cutaneous T-cell lymphoma
    J J Scarisbrick
    St John s Institute of Dermatology, St Thomas s Hospital, London, UK
    Clin Exp Dermatol 31:181-6. 2006
  6. doi request reprint Bexarotene therapy for mycosis fungoides and Sézary syndrome
    R A Abbott
    St John s Institute of Dermatology, St Thomas Hospital, London, UK
    Br J Dermatol 160:1299-307. 2009
  7. ncbi request reprint Secondary malignant neoplasms in 71 patients with Sézary syndrome
    J J Scarisbrick
    Skin Tumour Unit, St John s Institute of Dermatology, St Thomas Hospital, London, England
    Arch Dermatol 135:1381-5. 1999
  8. ncbi request reprint Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN
    J J Scarisbrick
    Skin Tumour Unit, St John s Institute Dermatology, St Thomas Hospital, London, United Kingdom
    Blood 95:2937-42. 2000
  9. ncbi request reprint A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma
    J J Scarisbrick
    Skin Tumour Unit, St John s Institute of Dermatology, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, U K
    Br J Dermatol 144:1010-5. 2001
  10. ncbi request reprint Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p
    J J Scarisbrick
    Skin Tumour Unit, St John s Institute Dermatology, St Thomas Hospital, London, UK
    J Invest Dermatol 117:663-70. 2001

Detail Information

Publications15

  1. ncbi request reprint Extracorporeal photopheresis in Sézary syndrome: hematologic parameters as predictors of response
    A V Evans
    Skin Tumour Unit, St John's Institute of Dermatology, St Thomas' Hospital, London, United Kingdom
    Blood 98:1298-301. 2001
    ..Alternatively, minimum tumor burden might be required for the induction of a cytotoxic response. Analysis of tumor-specific cytotoxic T cells is needed to investigate these possibilities further...
  2. doi request reprint U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease
    J J Scarisbrick
    St John s Institute of Dermatology, St Thomas Hospital, London, U K
    Br J Dermatol 158:659-78. 2008
    ..k...
  3. doi request reprint U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma
    J J Scarisbrick
    University Hospital Birmingham, Birmingham B15 2TH, U K
    Br J Dermatol 168:192-200. 2013
    ..Effects on neutrophils, glucose and liver function may also occur. These side-effects are dose dependent and may be controlled with corrective therapy or dose adjustments...
  4. ncbi request reprint Clinical features and diagnosis of 42 travellers with cutaneous leishmaniasis
    J J Scarisbrick
    Department of Dermatology, Middlesex Hospital, Mortimer Street, London W1N 8AA, UK
    Travel Med Infect Dis 4:14-21. 2006
    ....
  5. ncbi request reprint Staging and management of cutaneous T-cell lymphoma
    J J Scarisbrick
    St John s Institute of Dermatology, St Thomas s Hospital, London, UK
    Clin Exp Dermatol 31:181-6. 2006
    ....
  6. doi request reprint Bexarotene therapy for mycosis fungoides and Sézary syndrome
    R A Abbott
    St John s Institute of Dermatology, St Thomas Hospital, London, UK
    Br J Dermatol 160:1299-307. 2009
    ..Bexarotene (Targretin) is a synthetic retinoid which is licensed for the treatment of advanced refractory cutaneous T-cell lymphoma (CTCL)...
  7. ncbi request reprint Secondary malignant neoplasms in 71 patients with Sézary syndrome
    J J Scarisbrick
    Skin Tumour Unit, St John s Institute of Dermatology, St Thomas Hospital, London, England
    Arch Dermatol 135:1381-5. 1999
    ..Therefore, we reviewed the incidence of secondary malignant neoplasms in patients with SS...
  8. ncbi request reprint Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN
    J J Scarisbrick
    Skin Tumour Unit, St John s Institute Dermatology, St Thomas Hospital, London, United Kingdom
    Blood 95:2937-42. 2000
    ..Furthermore, abnormalities of PTEN may be important in the pathogenesis of mycosis fungoides, but our data imply that this gene is rarely inactivated by small deletions or point mutations. (Blood. 2000;95:2937-2942)..
  9. ncbi request reprint A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma
    J J Scarisbrick
    Skin Tumour Unit, St John s Institute of Dermatology, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, U K
    Br J Dermatol 144:1010-5. 2001
    ..The combination of fludarabine and cyclophosphamide shows synergistic toxicity in vitro and has been used to treat nodal non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukaemia...
  10. ncbi request reprint Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p
    J J Scarisbrick
    Skin Tumour Unit, St John s Institute Dermatology, St Thomas Hospital, London, UK
    J Invest Dermatol 117:663-70. 2001
    ..These results provide the basis for further studies defining more accurately chromosomal regions of deletions and candidate tumor suppressor genes involved in mycosis fungoides and Sézary syndrome...
  11. ncbi request reprint A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides
    F J Child
    Skin Tumour Unit, St John s Institute of Dermatology, St Thomas Hospital, London, UK
    Clin Exp Dermatol 29:231-6. 2004
    ..Although PUVA was more effective than ECP, neither treatment modality cleared malignant T-cells from the peripheral blood...
  12. ncbi request reprint Pseudocarcinomatous change in lymphomatoid papulosis and primary cutaneous CD30+ lymphoma: a clinicopathologic and immunohistochemical study of 6 patients
    J J Scarisbrick
    Skin Tumour Unit, St John s Institute Dermatology, St Thomas Hospital, London, UK
    J Am Acad Dermatol 44:239-47. 2001
    ..These cases demonstrate that PEH associated with CD30+ lymphoproliferative disease may closely resemble squamous cell carcinoma, thereby leading to inappropriate diagnosis and treatment...
  13. doi request reprint Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD
    F L Dignan
    St John s Institute of Dermatology, St Thomas Hospital, London, UK
    Bone Marrow Transplant 47:824-30. 2012
    ..OS at 3 years from the start of ECP was 69%. This study reports the largest series of patients receiving bimonthly ECP treatment for cGVHD, and confirms that ECP allows successful reduction of immunosuppression...
  14. ncbi request reprint Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides
    X Mao
    Skin Tumour Unit, St John s Institute of Dermatology, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, U K
    Br J Dermatol 147:464-75. 2002
    ..Data on genome-wide surveys for chromosome aberrations in primary cutaneous T-cell lymphoma (CTCL) are limited...
  15. doi request reprint How big is your hand and should you use it to score skin in cutaneous T-cell lymphoma?
    J J Scarisbrick
    Department of Dermatology, University Hospital Birmingham, Birmingham, B15 2TH, U K
    Br J Dermatol 169:260-5. 2013
    ..We recommend the use of the patient's palm to represent 0·5% BSA as the most convenient and reliable tool to measure surface area, and we introduce an iPhone application to record BSA electronically and calculate modified SWAT. ..